Journal
SCIENCE
Volume 327, Issue 5963, Pages 331-334Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1179907
Keywords
-
Categories
Funding
- NIH [GM54222, GM38784, GM38047]
- Robert H. Lurie Comprehensive Cancer Center
- U.S. Department of Energy, Office of Basic Energy Sciences
- National Center for Research Resources, NIH
- National Aeronautics and Space Administration
Ask authors/readers for more resources
Tetrathiomolybdate (TM) is an orally active agent for treatment of disorders of copper metabolism. Here we describe how TM inhibits proteins that regulate copper physiology. Crystallographic results reveal that the surprising stability of the drug complex with the metallochaperone Atx1 arises from formation of a sulfur-bridged copper-molybdenum cluster reminiscent of those found in molybdenum and iron sulfur proteins. Spectroscopic studies indicate that this cluster is stable in solution and corresponds to physiological clusters isolated from TM-treated Wilson's disease animal models. Finally, mechanistic studies show that the drug-metallochaperone inhibits metal transfer functions between copper-trafficking proteins. The results are consistent with a model wherein TM can directly and reversibly down-regulate copper delivery to secreted metalloenzymes and suggest that proteins involved in metal regulation might be fruitful drug targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available